Completed PHASE4 INTERVENTIONAL 4-arm NCT00913081

Advancing Niacin by Inhibiting Flushing (ANTI-FLUSH) (ANTI-FLUSH)

Advancing Niacin by Inhibiting FLUSHing: (ANTI-FLUSH)

Sponsor: Abbott

Conditions Flushing

Updated 8 times since 2017 Last updated: Feb 19, 2015 Started: Feb 28, 2009 Primary completion: Aug 31, 2009 Completion: Dec 31, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE4 clinical study on Flushing, this trial is completed. The trial is conducted by Abbott and has accumulated 8 data snapshots since 2009. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE4
Sep 2024 — Sep 2025 [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2023 — Jul 2024 [monthly]

Completed PHASE4
Dec 2022 — Jan 2023 [monthly]

Completed PHASE4

▶ Show 3 earlier versions

Jan 2021 — Dec 2022 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Feb 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Abbott
University of Pennsylvania

Data source: University of Pennsylvania

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Philadelphia, United States